In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase‐3β
Abstract
The two pathological lesions found in the brains of Alzheimer's disease patients, neurofibrillary tangles and neuritic plaques, are likely to be formed through a common pathway. Neurofibrillary tangles are intracellular aggregates of paired helical filaments, the main component of which is hyperphosphorylated forms of the microtubule-associated protein tau. Extracellular neuritic plaques and diffuse and vascular amyloid deposits are aggregates of beta-amyloid protein, a 4-kDa protein derived from the amyloid precursor protein (APP). Using conditions in vitro under which two proline-directed protein kinases, glycogen synthase kinase-3beta (GSK-3beta) and mitogen-activated protein kinase (MAPK), were able to hyperphosphorylate tau, GSK-3beta but not MAPK phosphorylated recombinant APPcyt. The sole site of phosphorylation in APPcyt by GSK-3beta was determined by phosphoamino acid analysis and phosphorylation of APPcyt mutant peptides to be Thr743 (numbering as for APP770). This site was confirmed by endoproteinase Glu-C digestion of APPcyt and peptide sequencing. The ability of GSK-3beta to phosphorylate APPcyt and tau provides a putative link between the two lesions and indicates a critical role of GSK-3beta in the pathogenesis of Alzheimer's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CDK5 and GSK3β are key kinases responsible for APP phosphorylation.
“Moreover, CDK5 and GSK3 are the key kinases responsible for the APP phosphorylation (Aplin et al., 1996;Iijima et al., 2000).”
From Retinoic Acid Attenuates β-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model (2008) · cites this paper as Aplin et al., 1996
Cited by
Sorted by citations
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,429 · see citing works
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 788 · see citing works
“Like some other protein kinases, GSK3 phosphorylates Thr668 in the cytoplasmic portion of AP”
BackgroundAPP processing is regulated by cytoplasmic phosphorylation
Lee, M.-S., Kao, S.-C., Lemere, C. A., Xia, W., Tseng, H.-C., Zhou, Y., Neve, R. L., Ahlijanian, M. K., & Tsai, L. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200301115 · Cited by 457 · see citing works
“Threonine 668 (T668) in the cytoplasmic domain of APP is also phosphorylated in vivo by a number of protein kinases, including GSK3 � , SAPK1b/JNK3, Cdc2, and Cdk5 (Suzuki et al., 1994; Aplin et al., 1996; Iijima et al., 2000; Standen et al., 2001).”
BackgroundPresenilin 1 associates with glycogen synthase kinase-3β and its substrate tau
Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M. H., Yamaguchi, H., Sugihara, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9637 · Cited by 404 · see citing works
What Are the bona fide GSK3 Substrates?
Sutherland, C. D. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/505607 · Cited by 349 · see citing works
“More specifically, GSK3 phosphorylates recombinant APP at Thr743 (numbering for APP 770), although whether this alters processing is not clear [27].”
BackgroundLaw, A. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00051-5 · Cited by 312 · see citing works
Rockenstein, E. M., Torrance, M., Adame, A., Mante, M., Bar‐On, P., Rose, J. B., Crews, L. A., & Masliah, E. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4321-06.2007 · Cited by 286 · see citing works
“…e Silva, 2003; Lee et al., 2003) and GSK3 [as well as stress-activated protein kinase (SAPK) and cyclindependent kinase-5 (CDK5)] plays a role in this process (Aplin et al., 1996; Iijima et al., 2000; Ryder et al., 2003), immunoblot analysis was performed with an antibody against APP-p (Thr668).”
BackgroundThe role of DYRK1A in neurodegenerative diseases
Węgiel, J., Gong, C., & Hwang, Y. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 288 · see citing works
Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E.-S., Block, M. L., Allsbrook, M., McDonald, M. P., & Fan, G.-H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3153-08.2008 · Cited by 269 · see citing works
“Moreover, CDK5 and GSK3 are the key kinases responsible for the APP phosphorylation (Aplin et al., 1996; Iijima et al., 2000).”
BackgroundDurairajan, S. S. K., Liu, L.-F., Lu, J.-H., Chen, L.-L., Yuan, Q., Chung, S. K., Huang, L., Li, X.-S., Huang, J.-D., & Li, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.016 · Cited by 271 · see citing works
Ando, K., Iijima, K., Elliott, J. I., Kirino, Y., & Suzuki, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104059200 · Cited by 261 · see citing works
Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M. M., Purganan, K., Wait, C., Petrova, A., Latendresse, S. J., Watson, G. S., et al. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00087-2 · Cited by 254 · see citing works
Müller, T., Meyer, H. E., Egensperger, R., & Marcus, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.002 · Cited by 242 · see citing works
Iijima, K., Ando, K., Takeda, S., Satoh, Y., Seki, T., Itohara, S., Greengard, P., Kirino, Y., Nairn, A. C., & Suzuki, T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751085.x · Cited by 234 · see citing works
Sutinen, E. M., Pirttilä, T., Anderson, G., Salminen, A., & Ojala, J. O. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-199 · Cited by 228 · see citing works
Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227 · see citing works
Patel, P., & Woodgett, J. R. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.11.011 · Cited by 211 · see citing works
Kirouac, L., Rajic, A. J., Cribbs, D. H., & Padmanabhan, J. (2017) · eneuro · doi:10.1523/eneuro.0149-16.2017 · Cited by 207 · see citing works
“Kinases such as GSK-3, JNK, extracellular signal–regulated kinase (ERK), cdk5, cdk4, and cdc2 phosphorylate this site on APP (Suzuki et al. 1994; Aplin et al. 1996; Iijima et al. 2000; Standen et al. 2001; Muresan and Muresan, 2005; Judge et al. 2011), and studies in AD brains have shown that…”
BackgroundIn vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases
Díaz‐Hernandéz, J. I., Gómez‐Villafuertes, R., León‐Otegui, M., Hontecillas‐Prieto, L., del Puerto, A., Trejo, J. L., Lucas, J. J., Garrido, J. J., Gualix, J., Miras‐Portugal, M. T., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.040 · Cited by 201 · see citing works
Flavonoids as Therapeutic Compounds Targeting Key Proteins Involved in Alzheimer’s Disease
Baptista, F. I., Henriques, A. G., Silva, A. M. S., Wiltfang, J., & Silva, O. A. B. D. C. E. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400213r · Cited by 189 · see citing works
Chang, K., Kim, H., Ha, T.-Y., Ha, J.-W., Shin, K. Y., Jeong, Y. H., Lee, J., Park, C., Kim, S., Baik, T.-K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02393-05 · Cited by 178 · see citing works
GSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177 · see citing works
“It has also been shown that the activation of GSK by Aβ in primary hippocampal cultures is specific to GSK-3β [86], and that the inhibition of GSK-3β prevents Aβ-induced toxicity to neurons [82, 84, 87, 88].”
BackgroundPharmacological effects of berberine and its derivatives: a patent update
Jin, Y., Khadka, D. B., & Cho, W. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118060 · Cited by 173 · see citing works
Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease
Wang, X., Zhou, X., Li, G., Zhang, Y., Wu, Y., & Song, W. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00294 · Cited by 173 · see citing works
“…tyrosinephosphorylationregulated kinase 1A (DYRK1A) and c-Jun N-terminal protein kinase (JNK) are involved in the process of its phosphorylation (Suzuki et al., 1994; Aplin et al., 1996; Oishi et al., 1997; Iijima et al., 2000; Standen et al., 2001; Ryoo et al., 2008; Mazzitelli et al., 2011).”
BackgroundGlutamate Slows Axonal Transport of Neurofilaments in Transfected Neurons
Ackerley, S., Grierson, A. J., Brownlees, J., Thornhill, P., Anderton, B. H., Leigh, P. N., Shaw, C. E., & Miller, C. C. J. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.1.165 · Cited by 170 · see citing works
“Not all Ser-Thr-Pro motifs are phosphorylated under these conditions, since we have shown that Thr668 in the Alzheimer’s disease amyloid precursor protein, which is a known in vivo phosphorylation site, is not phosphorylated by MAPK (Aplin et al., 1996).”
Self-citationAshley, J., Packard, M. C., Ataman, B., & Budnik, V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1144-05.2005 · Cited by 164 · see citing works
“A variety of kinases are able to phosphorylate the APP cytoplasmic domain, resulting in regulation of APP metabolism and function (Aplin et al., 1996; Ando et al., 2001; Inomata et al., 2003; Standen et al., 2003).”
BackgroundDeconstructing GSK‐3: The Fine Regulation of Its Activity
Medina, M., & Wandosell, F. G. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/479249 · Cited by 163 · see citing works
“per se decreases Aβ production in cells and in an animal model of amyloidosis [61, 120], most likely through a mechanism involving inhibition of γ-secretase [137].”
BackgroundLithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100
Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.-M., Yamaguchi, H., & Takashima, A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02583-6 · Cited by 161 · see citing works
Molecular connexions between dementia and diabetes
Cole, A. R., Astell, A. J., Green, C., & Sutherland, C. D. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.004 · Cited by 161 · see citing works
Inomata, H., Nakamura, Y., Hayakawa, A., Takata, H., Suzuki, T., Miyazawa, K., & Kitamura, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212160200 · Cited by 158 · see citing works
GSK3 and Alzheimer’s disease: facts and fiction…
Kremer, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00017 · Cited by 155 · see citing works
JNK regulates APP cleavage and degradation in a model of Alzheimer's disease
Colombo, A. V., Bastone, A., Ploia, C., Sclip, A., Salmona, M., Forloni, G., & Borsello, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.014 · Cited by 158 · see citing works
Gourmaud, S., Shou, H., Irwin, D. J., Sansalone, K., Jacobs, L. M., Lucas, T. H., Marsh, E. D., Davis, K. A., Jensen, F. E., & Talos, D. M. (2020) · Brain · doi:10.1093/brain/awz381 · Cited by 155 · see citing works
Flavonoid‐mediated presenilin‐1 phosphorylation reduces Alzheimer's disease β‐amyloid production
Rezai-Zadeh, K. P., Shytle, R. D., Bai, Y., Tian, J., Hou, H., Mori, T., Zeng, J., Obregon, D. F., Town, T., & Tan, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00344.x · Cited by 153 · see citing works
Lithium and Therapeutic Targeting of GSK-3
Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 145 · see citing works
JNK Plays a Key Role in Tau Hyperphosphorylation in Alzheimer's Disease Models
Ploia, C., Antoniou, X., Sclip, A., Grande, V., Cardinetti, D., Colombo, A., Canu, N., Benussi, L., Ghidoni, R., Forloni, G., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110320 · Cited by 145 · see citing works
Liu, H., Zhao, G., Zhang, H., & Li-de, S. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.008 · Cited by 141 · see citing works
Ramelot, T. A., & Nicholson, L. K. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4535 · Cited by 138 · see citing works
Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors
Jacobsen, K. T., & Iverfeldt, K. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0020-8 · Cited by 139 · see citing works
“been implicated to phosphorylate APP at Thr668 [67, 68].”
BackgroundThe role of intracellular zinc release in aging, oxidative stress, and Alzheimer’s disease
McCord, M. C., & Aizenman, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00077 · Cited by 137 · see citing works
“These calciumdependent phosphorylation events are mediated by GSK-3β, a kinase known for its role in the phosphorylation of both tau and APP (Aplin et al., 1996) that has previously been shown to be activated downstream of ER calcium release (Hartigan and Johnson, 1999).”
BackgroundInfluentialMills, J., Laurent Charest, D., Lam, F., Beyreuther, K., Ida, N., Pelech, S. L., & Reiner, P. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09415.1997 · Cited by 134 · see citing works
Stone, J. R., Singleton, R. H., & Povlishock, J. T. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02485-9 · Cited by 132 · see citing works
Therapeutic strategies for tau mediated neurodegeneration
Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 129 · see citing works
Dionísio, P. A., Amaral, J. D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., & Rodrigues, C. M. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.034 · Cited by 127 · see citing works
Divergent roles of GSK3 and CDK5 in APP processing
Ryder, J. W., Yuan, S., Liu, F., Li, B., Zhou, Y., & Ni, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.014 · Cited by 126 · see citing works
Cdk5, a therapeutic target for Alzheimer's disease?
Tsai, L., Lee, M.-S., & Cruz, J. C. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.019 · Cited by 122 · see citing works
Regulation of Amyloid β-Protein Precursor by Phosphorylation and Protein Interactions
Suzuki, T., & Nakaya, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800003200 · Cited by 122 · see citing works
Standen, C. L., Brownlees, J., Grierson, A. J., Kesavapany, S., Lau, K., McLoughlin, D. M., & Miller, C. C. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00102.x · Cited by 121 · see citing works
Pierrot, N., Santos, S. F., Feyt, C., Morel, M., Brion, J., & Octave, J. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606015200 · Cited by 118 · see citing works
Mudher, A. K., Chapman, S. C., Richardson, J. C., Asuni, A. A., Gibb, G., Pollard, C. C., Killick, R., Iqbal, T. A., Raymond, F. L., Varndell, I. M., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-14-04987.2001 · Cited by 122 · see citing works
“APP can be directly phosphorylated by GSK-3b ( Aplin et al., 1996 ), and when this happens the cellular maturation of APP is altered (Aplin et al., 1997).”
BackgroundSelf-citationNeurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120 · see citing works
Blaikie, L., Kay, G., & Lin, P. K. T. (2019) · MedChemComm · doi:10.1039/c9md00337a · Cited by 113 · see citing works
Phosphorylation Signaling in APP Processing in Alzheimer’s Disease
Zhang, T., Chen, D., & Lee, T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010209 · Cited by 114 · see citing works
Liu, F., Yuan, S., Li, B., Zhou, Y., Ryder, J. W., Gonzalez‐DeWhitt, P. A., May, P. C., & Ni, B. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00714-2 · Cited by 110 · see citing works
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
Mendes, C. T., Mury, F. B., Moreira, E. D. S., Alberto, F., Forlenza, O. V., Dias‐Neto, E., & Gattaz, W. F. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0828-5 · Cited by 110 · see citing works
“GSK3 has been shown to phosphorylate several brain proteins, including amyloid precursor protein (APP) [ 1 ], neurofilaments [10] and the microtubule-associated protein Tau [23].”
BackgroundJin, N., Yin, X., Yu, D., Cao, M., Gong, C., Iqbal, K., Ding, F., Gu, X., & Liu, F. (2015) · Scientific Reports · doi:10.1038/srep08187 · Cited by 107 · see citing works
Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98 · see citing works
Piacentini, R., Puma, D. D. L., Ripoli, C., Marcocci, M. E., Chiara, G. D., Garaci, E., Palamara, A. T., & Grassi, C. (2015) · Scientific Reports · doi:10.1038/srep15444 · Cited by 97 · see citing works
Insulin Has Multiple Antiamyloidogenic Effects on Human Neuronal Cells
Pandini, G., Pace, V., Copani, A., Squatrito, S., Milardi, D., & Vigneri, R. (2012) · Endocrinology · doi:10.1210/en.2012-1661 · Cited by 97 · see citing works
AßT Amyloidogenesis: Unique, or Variation on a Systemic Theme
Kisilevsky, R., Fraser, P. E., & Benson, M. D. (1997) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239709082674 · Cited by 92 · see citing works
Onishi, T., Iwashita, H., Uno, Y., Kunitomo, J., Saitoh, M., Kimura, E., Fujita, H., Uchiyama, N., Kori, M., & Takizawa, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07532.x · Cited by 91 · see citing works
Pin1 in Alzheimer's disease: Multiple substrates, one regulatory mechanism?
Balaštík, M., Lim, J., Pastorino, L., & Lu, K. P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.01.006 · Cited by 90 · see citing works
A Unifying Hypothesis of Alzheimer's Disease. IV. Causation and Sequence of Events
Heininger, K. (2000) · Reviews in the Neurosciences · doi:10.1515/revneuro.2000.11.s1.213 · Cited by 138 · see citing works
“…Ishiguro et al., 1993; Hartigan and Johnson, 1999; Sayas et al., 1999) and APP cytoplasmic phosphorylation and accumulation (Takashima et al., 1995; Aplin et al., 1996, 1997), establishing a reinforcing GSKAPP-Aß cycle which is modulated by the cellular Ca2+ -energy redox homeostasis (Hartigan and…”
Rockenstein, E. M., Torrance, M., Mante, M., Adame, A., Paulino, A., Rose, J. B., Crews, L. A., Moessler, H., & Masliah, E. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20818 · Cited by 88 · see citing works
“, 2000), GSK3b (Aplin et al., 1996), and SAPK1 (Standen et al.”
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 72 · see citing works
Role of GSK‐3β in Alzheimer's disease pathology
Planel, E., Sun, X., & Takashima, A. (2002) · Drug Development Research · doi:10.1002/ddr.10100 · Cited by 85 · see citing works
Ma, S. L., Pastorino, L., Zhou, X. Z., & Lu, K. P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c111.298596 · Cited by 85 · see citing works
GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease
Bhat, R. V., & Budd, S. L. (2002) · Neurosignals · doi:10.1159/000067423 · Cited by 85 · see citing works
Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease
Oliveira, J. M., Costa, M. G. C., Cachide, M., Silva, O. A. B. D. C. E., & Henriques, A. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170176 · Cited by 82 · see citing works
KESTREL: a powerful method for identifying the physiological substrates of protein kinases
Cohen, P., & Knebel, A. (2005) · Biochemical Journal · doi:10.1042/bj20051545 · Cited by 83 · see citing works
Muresan, Z. L., & Mureşan, V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0152-05.2005 · Cited by 80 · see citing works
“Potential candidates are cyclin-dependent kinase 5 (Cdk5) (Iijima et al., 2000), c-Jun NH2-terminal kinase (JNK) (Standen et al., 2001; Taru et al., 2002; Scheinfeld et al., 2003), and glycogen synthase kinase 3 (Aplin et al., 1996).”
BackgroundFajardo, V. A., Fajardo, V. A., LeBlanc, P. J., & MacPherson, R. E. K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170744 · Cited by 78 · see citing works
Role of APP phosphorylation in FE65‐dependent gene transactivation mediated by AICD
Nakaya, T., & Suzuki, T. (2006) · Genes to Cells · doi:10.1111/j.1365-2443.2006.00968.x · Cited by 78 · see citing works
GSK3 as a Sensor Determining Cell Fate in the Brain
Cole, A. R. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00004 · Cited by 76 · see citing works
Ding, Y., Qiao, A., & Fan, G.-H. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.022 · Cited by 76 · see citing works
“In the AD brain, tau is hyperphosphorylated at more than 38 different sites, which interferes with the affinity of tau-microtubule binding (Aplin et al., 1996) and causes neurofibrillary tangle formation (Knafo et al.”
Liu, G., Zhang, Y., Yao, X., Zhang, C., Fang, J., Wang, Q., & Wang, J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.012 · Cited by 72 · see citing works
Naert, G., Ferré, V. M., Meunier, J., Keller, E., Malmström, S., Givalois, L., Carreaux, F., Bazureau, J. P., & Maurice, T. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.018 · Cited by 75 · see citing works
Protein Phosphorylation and APP Metabolism
Silva, E. F. D. C. E., & Silva, O. A. B. D. C. E. (2003) · Neurochemical Research · doi:10.1023/a:1025630627319 · Cited by 70 · see citing works
“This same residue is phosphorylated in vitro by GSK-3 ( 31 ) and in vivo by Jnk-3 (32), the major stress-activated protein kinase in the nervous system (also known as SAPK1b or stress-activated protein kinase 1b).”
Kanninen, K. M., White, A. R., Koıstınaho, J., & Malm, T. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/985085 · Cited by 68 · see citing works
“GSK-3β can also directly phosphorylate APP in vitro [28], and, interestingly, AD-related mutated presenilin-1 is able to both directly and indirectly activate GSK-3β [29, 30].”
BackgroundGlycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome
Mines, M. A., & Jope, R. S. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00035 · Cited by 68 · see citing works
Molecular Cloning and Characterization of the Human Glycogen Synthase Kinase-3β Promoter
Lau, K., Miller, C. C. J., Anderton, B. H., & Shaw, P. (1999) · Genomics · doi:10.1006/geno.1999.5875 · Cited by 67 · see citing works
Self-citationKim, B., Elzinga, S. E., Henn, R. E., McGinley, L. M., & Feldman, E. L. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104541 · Cited by 66 · see citing works
Buoso, E., Lanni, C., Schettini, G., Govoni, S. M., & Racchi, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.05.002 · Cited by 66 · see citing works
“This residue can be phosphorylated by neuronal yclin-dependent kinase 5 (Cdk5) in neurons [27], by Cdc2 kinase n dividing cells [28,26], by glycogen synthase kinase 3 (GSK) and by stress-activated protein kinase 1 in vitro [29,30].”
BackgroundEffects of endogenous β‐amyloid overproduction on tau phosphorylation in cell culture
Wang, Z., Li, H., Li, X., Zhang, Q., Tian, Q., Wang, Q., Xu, H., & Wang, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03956.x · Cited by 65 · see citing works
Zhao, L., Wang, Y., Sun, N., Liu, X., Li, L., & Shi, J. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.08.034 · Cited by 65 · see citing works
Sumioka, A., Nagaishi, S., Yoshida, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504278200 · Cited by 64 · see citing works
Sano, Y., Nakaya, T., Pedrini, S., Takeda, S., Iijima‐Ando, K., Iijima, K., Mathews, P. M., Itohara, S., Gandy, S., & Suzuki, T. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000051 · Cited by 63 · see citing works
Pin1 promotes production of Alzheimer’s amyloid β from β-cleaved amyloid precursor protein
Akiyama, H., Shin, R., Uchida, C., Kitamoto, T., & Uchida, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.130 · Cited by 62 · see citing works
O’Leary, O. F., & Nolan, Y. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0213-z · Cited by 63 · see citing works
“GSK-3 has also been shown to interact with the proteins amyloid precursor protein (APP) [17], tau [18] and presenilin-1 [19], which are implicated in the pathology of Alzheimer’s disease (AD).”
BackgroundGlycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Aghdam, S. Y., & Barger, S. W. (2007) · Current Alzheimer Research · doi:10.2174/156720507779939832 · Cited by 61 · see citing works
Haddad, J. J. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.06.002 · Cited by 61 · see citing works
Isolation and chromosomal mapping of human glycogen synthase kinase-3 α and -3β encoding genes
Shaw, P., Davies, A. F., Lau, K., Garcia-Barceló, M., Waye, M. M. Y., Lovestone, S., Miller, C. C. J., & Anderton, B. H. (1998) · Genome · doi:10.1139/gen-41-5-720 · Cited by 67 · see citing works
Self-citationHuang, W., Chen, P., Yu, K., Han, Y., Song, M., & Li, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.114 · Cited by 59 · see citing works
Shin, R., Ogino, K., Shimabuku, A., Taki, T., Nakashima, H., Ishihara, T., & Kitamoto, T. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0211-z · Cited by 57 · see citing works
Eisele, Y. S., Baumann, M., Klebl, B., Nordhammer, C., Jucker, M., & Kilger, E. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0035 · Cited by 54 · see citing works
“Among the several kinases that have been described to phosphorylate APP at T668 (Suzuki et al., 1994; Aplin et al., 1996; Iijima et al., 2000; Taru and Suzuki, 2004; Kimberly et al., 2005), the c-Jun NH2terminal kinase (JNK) seems to play an important role in vivo (Kimberly et al.”
BackgroundImmune and myodegenerative pathomechanisms in inclusion body myositis
Keller, C. W., Schmidt, J., & Lünemann, J. D. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.419 · Cited by 51 · see citing works
“183–185 It is therefore considered to be more cytotoxic and the predominant isoform to be accumulated as oligomers in IBM muscle.186,187 Congophilic Ab is detected in up to 70% of IBM muscle fibers and mostly found in nonvacuolated areas.188 Ab peptides are generated via the sequential cleavage of the transmembrane gl…”
BackgroundThe role of glycoproteins in neural development, function, and disease
Breen, K. C., Coughlan, C. M., & Hayes, F. D. (1998) · Molecular Neurobiology · doi:10.1007/bf02740643 · Cited by 51 · see citing works
Kim, B. M., You, M., Chen, C.-H., Suh, J., Tanzi, R. E., & Lee, T. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw114 · Cited by 52 · see citing works
Muresan, Z. L., & Mureşan, V. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0625 · Cited by 50 · see citing works
“The phosphorylated residue is Thr668 (numbering for APP695); Cdk5 (Iijima et al., 2000), GSK3 ( Aplin et al., 1996 ), and c-Jun NH2-terminal kinase (JNK; Standen et al., 2001; Muresan and Muresan, 2005a) are the candidate kinases.”
BackgroundAcevedo, K. M., Opazo, C., Norrish, D., Challis, L. M., Li, Q., White, A. R., Bush, A. I., & Camakaris, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538710 · Cited by 48 · see citing works
“APP is phosphorylated at Thr-668 in vitro and in vivo by a number of kinases including glycogen synthase kinase 3 , Jun N-terminal kinase-3 (JNK3), cell division cycle protein (Cdc2), and cyclindependent kinase 5 (Cdk5) (7, 29 –32).”
BackgroundInfluential
- Authors
- Aplin, A. E., Gibb, G. M., Jacobsen, J. S., Gallo, J., & Anderton, B. H.
- Corresponding author
- Aplin, Andrew E.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 1996-08
- Volume
- 67
- Issue
- 2
- Pages
- 699-707
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2069584842
- Cited by
- 201
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 9 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 1 · 2017: 11 · 2016: 10 · 2015: 7 · 2014: 13 · 2013: 6 · 2012: 7
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid precursor protein, glycogen synthase kinase-3β, protein phosphorylation, Alzheimer's disease, tau hyperphosphorylation, neurofibrillary tangles, neuritic plaques, amyloid-beta, mitogen-activated protein kinase, phosphorylation site mapping
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cytoplasm, Humans, Molecular Sequence Data, Phosphorylation, Phosphothreonine, Protein-Tyrosine Kinases, Amyloid beta-Protein Precursor, Calcium-Calmodulin-Dependent Protein Kinases, DNA Primers, Mitogen-Activated Protein Kinase 1, Glycogen Synthase Kinases, Glycogen Synthase Kinase 3, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review